Beijing Cancer Prevention & Treatment Society
2 clinical trials · Sponsor
◉ Watch Beijing Cancer Prevention & Treatment Society
| Record | Firm | Date |
|---|---|---|
| A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC (NCT06422546) | Beijing Cancer Prevention & Treatment Society | 2022-01-15 |
| Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib (NCT04769388) | Beijing Cancer Prevention & Treatment Society | 2021-12-28 |
Track Beijing Cancer Prevention & Treatment Society automatically
Every clearance here is in the API, with alerts when new ones post.